Amphastar Pharmaceuticals (AMPH) Debt to Equity (2016 - 2025)
Amphastar Pharmaceuticals (AMPH) has 13 years of Debt to Equity data on record, last reported at $0.78 in Q3 2025.
- For Q3 2025, Debt to Equity fell 4.31% year-over-year to $0.78; the TTM value through Sep 2025 reached $0.78, down 4.31%, while the annual FY2024 figure was $0.82, 10.93% down from the prior year.
- Debt to Equity reached $0.78 in Q3 2025 per AMPH's latest filing, down from $0.8 in the prior quarter.
- Across five years, Debt to Equity topped out at $1.07 in Q3 2023 and bottomed at $0.08 in Q2 2021.
- Average Debt to Equity over 5 years is $0.52, with a median of $0.78 recorded in 2025.
- Peak YoY movement for Debt to Equity: skyrocketed 616.19% in 2023, then decreased 23.58% in 2024.
- A 5-year view of Debt to Equity shows it stood at $0.17 in 2021, then fell by 16.92% to $0.14 in 2022, then surged by 542.83% to $0.92 in 2023, then dropped by 10.93% to $0.82 in 2024, then dropped by 4.53% to $0.78 in 2025.
- Per Business Quant database, its latest 3 readings for Debt to Equity were $0.78 in Q3 2025, $0.8 in Q2 2025, and $0.8 in Q1 2025.